(Endometrial Cancer) Is Lenvatinib + Keytruda Effective?
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- February 3, 2022
- Reading time: 1 minute
On January 19, 2022, Vicky Makker of Memorial Sloan Kettering Cancer Center published results in The New England Journal of Medicine from the Study 309–KEYNOTE-775 Phase III clinical trial evaluating lenvatinib plus the anti-PD-1 antibody Keytruda (pembrolizumab) in advanced endometrial cancer patients with prior platinum-based chemotherapy.
The Study 309–KEYNOTE-775 Phase III trial randomized previously platinum-treated advanced endometrial cancer patients (N=827) in a 1:1 ratio to the lenvatinib arm (lenvatinib 20 mg once daily + Keytruda 200 mg every 3 weeks, N=411) or the chemotherapy arm (N=416). Primary endpoints were progression-free survival (PFS) and overall survival (OS).
Of the 827 patients, 697 were pMMR and 130 were dMMR.
Progression-Free Survival (Primary Endpoint): Median PFS was 7.2 months in the lenvatinib arm versus 3.8 months in the chemotherapy arm, representing a 44% reduction in the risk of progression or death in the lenvatinib arm. Among pMMR patients, median PFS was 6.6 months versus 3.8 months, with a 40% reduction in risk.
Overall Survival (Primary Endpoint): Median OS was 18.3 months in the lenvatinib arm versus 11.4 months in the chemotherapy arm, representing a 38% reduction in the risk of death. Among pMMR patients, median OS was 17.4 months versus 12.0 months, with a 32% reduction in risk.
Safety: Grade ≥3 adverse events occurred in 88.9% of lenvatinib arm patients versus 72.7% in the chemotherapy arm.
Based on the Study 309–KEYNOTE-775 results, Vicky Makker and colleagues concluded that lenvatinib plus Keytruda demonstrated significantly improved PFS and OS compared with chemotherapy in previously platinum-treated advanced endometrial cancer patients.
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2108330?query=featured_home
- Immunotherapy
- Clinical trial drugs
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4